NCT07011849 2025-08-13
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT01130623 2017-07-02
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01236586 2017-07-02
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01320787 2014-10-23
18-F-Fluoroacetate as PET Imaging Agent
M.D. Anderson Cancer Center
Phase 1 Withdrawn